Table 5.

Outcomes of patients receiving second transplant by patient groups

OS			HR	95% CI		P
	Same donor as first	(v. different donor)	2.31	0.77	6.92	0.16
	Performed 2005–2009	(v. 2010–2015)	1.82	0.65	5.0	0.28
	Age > 45	(v. <45)	1.8	0.73	4.42	0.19
	Refractory or Progressive Disease	(v. CR or PR)	2.56	1.03	6.25	0.06
	Relapse diagnosed within 6 months	(v. > 6 months)	2.49	1.0	6.2	0.07
	Acute GVHD from first transplant	(v. no GVHD)	2.12	0.87	5.17	0.11
	Second graft contained new haplotype	(v. no new haplotype)	0.36	0.14	0.9	0.02
EFS
	Same donor as first	(v. different donor)	1.54	0.52	4.5	0.46
	Performed 2005–2009	(v. 2010–2015)	1.89	0.2	1.44	0.25
	Age > 45	(v. <45)	2.32	0.99	5.44	0.05
	Refractory or Progressive Disease	(v. CR or PR)	2.44	1	5.88	0.07
	Relapse diagnosed within 6 months	(v. > 6 months)	2.53	1.03	6.22	0.06
	Acute GVHD from first transplant	(v. no GVHD)	1.50	0.65	3.44	0.35
	Second graft contained new haplotype	(v. no new haplotype)	0.50	0.22	1.14	0.09
Cumulative Incidence of Relapse
	Same donor as first	(v. different donor)	0.76	0.13	4.51	0.77
	Performed 2005–2009	(v. 2010–2015)	1.11	0.23	5.26	0.89
	Age > 45	(v. <45)	5.29	1.13	24.74	0.03
	Refractory or Progressive Disease	(v. CR or PR)	1.67	0.45	6.25	0.44
	Relapse diagnosed within 6 months	(v. > 6 months)	1.43	0.38	5.41	0.59
	Acute GVHD from first transplant	(v. no GVHD)	0.44	0.1	1.87	0.27
	Second graft contained new haplotype	(v. no new haplotype)	0.81	0.25	2.59	0.73
Cumulative Incidence of Non-Relapse Mortality
	Same donor as first	(v. different donor)	2.62	1.02	6.71	0.05
	Performed 2005–2009	(v. 2010–2015)	1.79	0.44	7.14	0.42
	Age > 45	(v. <45)	1.09	0.38	3.18	0.87
	Refractory or Progressive Disease	(v. CR or PR)	2.08	0.66	6.67	0.21
	Relapse diagnosed within 6 months	(v. > 6 months)	2.09	0.61	7.2	0.24
	Acute GVHD from first transplant	(v. no GVHD)	3.44	1.19	9.94	0.02
	Second graft contained new haplotype	(v. no new haplotype)	0.4	0.12	1.32	0.13